Li Baokun, Han Jiachao, Wang Feifei, Yu Bin, Wang Guiying, Yang Fei
The Second Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Department of General Surgery II, Handan Central Hospital, Handan, Hebei, China.
Front Oncol. 2025 May 15;15:1562634. doi: 10.3389/fonc.2025.1562634. eCollection 2025.
To identify potential factors influencing the survival prognosis of locally advanced rectal cancer patients receiving neoadjuvant chemoradiotherapy.
A retrospective study was conducted to collect data from January 2009 to December 2020 on 270 patients with locally advanced rectal cancer who were admitted to the Fourth Hospital of Hebei Medical University. The clinical data of patients before and after neoadjuvant chemoradiotherapy and postoperative treatment were compiled. The endpoints of the study were disease-free survival and overall survival of the patients. The univariate and multivariable regression analysis were used to identify factors that influence the patients' survival prognosis.
Univariate analysis showed that factors associated with good prognosis in neoadjuvant chemotherapy patients included age <65 years, CEA value ≤5ng/mL, lymphocyte count >1.5×10/L, normal albumin level, NLR ≤2.64, SII ≤683.16, PNI >49.23, tumor distance from the anal margin >5cm, tumor length ≤5cm, tumor invasion of the bowel wall ratio ≤50%, lower T stage and N stage, good tumor regression response, absence of KRAS gene mutation, and mismatch repair protein deficiency. And multivariate analysis showed that age (HR=0.385, P=0.007), NLR (HR=0.294, P=0.011), cT stage (HR=0.287, P<0.001), and tumor regression grade (HR=0.273, P<0.001) were significant factors influencing DFS in patients receiving neoadjuvant chemoradiotherapy. For OS, age (HR=0.497, P=0.035), cT stage (HR=0.387, P=0.001), and tumor regression grade (HR=0.307, P<0.001) were significant factors influencing OS in patients receiving neoadjuvant chemoradiotherapy.
Age, cT stage, NLR, and tumor regression grade are significant factors influencing DFS and OS in patients with locally advanced rectal cancer. Younger age, lower cT stage, lower NLR value, and lower tumor regression grade are associated with better survival prognosis.
确定影响接受新辅助放化疗的局部晚期直肠癌患者生存预后的潜在因素。
进行一项回顾性研究,收集2009年1月至2020年12月在河北医科大学第四医院收治的270例局部晚期直肠癌患者的数据。整理患者新辅助放化疗前后及术后治疗的临床资料。研究终点为患者的无病生存期和总生存期。采用单因素和多因素回归分析确定影响患者生存预后的因素。
单因素分析显示,新辅助化疗患者预后良好的相关因素包括年龄<65岁、癌胚抗原(CEA)值≤5ng/mL、淋巴细胞计数>1.5×10⁹/L、白蛋白水平正常、中性粒细胞与淋巴细胞比值(NLR)≤2.64、全身炎症反应指数(SII)≤683.16、预后营养指数(PNI)>49.23、肿瘤距肛缘距离>5cm、肿瘤长度≤5cm、肿瘤侵犯肠壁比例≤50%、较低的T分期和N分期、良好的肿瘤退缩反应、无KRAS基因突变以及错配修复蛋白缺陷。多因素分析显示,年龄(风险比[HR]=0.385,P=0.007)、NLR(HR=0.294,P=0.011)、cT分期(HR=0.287,P<0.001)和肿瘤退缩分级(HR=0.273,P<0.001)是影响接受新辅助放化疗患者无病生存期的显著因素。对于总生存期,年龄(HR=0.497,P=0.035)、cT分期(HR=0.387,P=0.001)和肿瘤退缩分级(HR=0.307,P<0.001)是影响接受新辅助放化疗患者总生存期的显著因素。
年龄、cT分期、NLR和肿瘤退缩分级是影响局部晚期直肠癌患者无病生存期和总生存期的显著因素。年龄较小、cT分期较低、NLR值较低和肿瘤退缩分级较低与较好的生存预后相关。